Zydus Lifesciences Limited has officially notified stock exchanges about its upcoming Board of Directors meeting scheduled for February 9, 2026. The pharmaceutical company issued the notice on January 27, 2026, in compliance with regulatory requirements under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board of Directors meeting will be held on Monday, February 9, 2026, with the primary agenda being the consideration and approval of unaudited financial results. The meeting will focus on reviewing the company's performance for the quarter and nine months ended December 31, 2025, representing the third quarter of fiscal year 2026.

Trading Window Restrictions

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, Zydus Lifesciences has implemented mandatory trading window restrictions. The trading window will remain closed for all Directors and Designated Persons of the company until Wednesday, February 11, 2026. Normal trading activities will resume on Thursday, February 12, 2026.

Corporate Communication

The official notice was signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), and submitted to both major stock exchanges where the company is listed. The communication was addressed to BSE Limited (Code: 532321) and National Stock Exchange of India Limited (Code: Zyduslife), ensuring compliance with dual listing requirements.

The company maintains its registered office at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), near Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. This board meeting announcement follows standard corporate governance practices for publicly listed pharmaceutical companies in India.

Zydus Lifesciences Limited has announced the completion of a United States Food and Drug Administration (USFDA) inspection at its Unit-2 manufacturing plant located in Ankleswar, Gujarat. The pharmaceutical company disclosed this development through a press release dated January 23, 2026, as part of its regulatory compliance obligations.

Inspection Details and Timeline

The USFDA inspection was conducted over a five-day period from January 19 to January 23, 2026. The regulatory review focused on the company's Unit-2 manufacturing facility at Ankleswar, which is part of Zydus Lifesciences' manufacturing operations in Gujarat.

Inspection Outcome

The inspection concluded with 3 observations from the USFDA. Significantly, the company emphasized that there were no data integrity related observations during the inspection process. Data integrity issues are typically considered more serious regulatory concerns, and their absence suggests the inspection focused on other operational or compliance aspects.

Company Response and Next Steps

Zydus Lifesciences has stated its commitment to addressing the observations received during the inspection. The company indicated it will work closely with the USFDA to resolve the identified issues expeditiously. This collaborative approach demonstrates the company's focus on maintaining regulatory compliance and addressing any concerns raised by the regulatory authority.

Regulatory Disclosure

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation requires listed companies to disclose material events and information that could impact investor decisions, including regulatory inspections and their outcomes.

The disclosure was communicated to both the BSE Limited and the National Stock Exchange of India Limited on January 23, 2026, ensuring transparency with investors and market participants regarding this regulatory development.